BR0211124A - Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos para alterar a atividade de transdução de sinal de receptores gabaa, para o tratamento de ansiedade, depressão, distúrbio do sono, esquizofrenia, distúrbio de hiperatividade-falta de atenção, ou para a melhora de memória, e para demonstrar a presença de receptores gabaa em uma célula ou amostra de tecido, composição farmacêutica embalada, e, uso de um composto ou sal - Google Patents
Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos para alterar a atividade de transdução de sinal de receptores gabaa, para o tratamento de ansiedade, depressão, distúrbio do sono, esquizofrenia, distúrbio de hiperatividade-falta de atenção, ou para a melhora de memória, e para demonstrar a presença de receptores gabaa em uma célula ou amostra de tecido, composição farmacêutica embalada, e, uso de um composto ou salInfo
- Publication number
- BR0211124A BR0211124A BR0211124-1A BR0211124A BR0211124A BR 0211124 A BR0211124 A BR 0211124A BR 0211124 A BR0211124 A BR 0211124A BR 0211124 A BR0211124 A BR 0211124A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- pharmaceutical composition
- disorder
- salt
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
"COMPOSTO OU UM SAL FARMACEUTICAMENTE ACEITáVEL DO MESMO, COMPOSIçãO FARMACêUTICA, MéTODOS PARA ALTERAR A ATIVIDADE DE TRANSDUçãO DE SINAL DE RECEPTORES GABA~ A~, PARA O TRATAMENTO DE ANSIEDADE, DEPRESSãO, DISTúRBIO DO SONO, ESQUIZOFRENIA, DISTúRBIO DE HIPERATIVIDADE - FALTA DE ATENçãO, OU PARA A MELHORA DE MEMóRIA, E PARA DEMONSTRAR A PRESENçA DE RECEPTORES GABA~ A~ EM UMA CéLULA OU AMOSTRA DE TECIDO, COMPOSIçãO FARMACêUTICA EMBALADA, E, USO DE UM COMPOSTO OU SAL". A invenção refere-se a compostos heteroarila bicíclico fundidos substituídos com heteroarila, como imidazopiridinas, imiazopirazinas, imidazopiridizinas, imidazopirimidinas e imidazotiazóis substituídos com heteroarila, que podem ser descritos pela fórmula (I), A invenção refere-se particularmente a estas compostos que ligam com elevada seletividade e elevada afinidade ao sitio de benzodiazepina de receptores GABA~ A~. Esta invenção também refere-se a composições farmacêuticas compreendendo estes compostos e ao uso destes compostos no tratamento de determinadas doenças do sistema nervoso central (CNS). Os processos para preparar compostos de fórmula I e fórmula II são descritos. Esta invenção também refere-se ao uso de benzimidazóis, piridilmidiazóis e compostos heteroarila bicíclicos relacionadas de fórmula I ou fórmula II em combinação com um ou mais de outros agentes de CNS para potenciar os efeitos de outros agentes CNS. Adicionalmente, esta invenção refere-se ao uso destes compostos como sondas para a localização de receptores GABA~ A~ em seções de tecido.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30553301P | 2001-07-13 | 2001-07-13 | |
PCT/US2002/022130 WO2003006471A1 (en) | 2001-07-13 | 2002-07-12 | Heteroaryl substituted fused bicyclic heteroaryl compounds as gabaa receptor ligands |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0211124A true BR0211124A (pt) | 2004-06-29 |
Family
ID=23181185
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0211124-1A BR0211124A (pt) | 2001-07-13 | 2002-07-12 | Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos para alterar a atividade de transdução de sinal de receptores gabaa, para o tratamento de ansiedade, depressão, distúrbio do sono, esquizofrenia, distúrbio de hiperatividade-falta de atenção, ou para a melhora de memória, e para demonstrar a presença de receptores gabaa em uma célula ou amostra de tecido, composição farmacêutica embalada, e, uso de um composto ou sal |
Country Status (16)
Country | Link |
---|---|
US (2) | US6936617B2 (pt) |
EP (1) | EP1406906A1 (pt) |
JP (1) | JP2005505518A (pt) |
KR (1) | KR20040015356A (pt) |
CN (2) | CN101220027A (pt) |
AR (1) | AR036168A1 (pt) |
BR (1) | BR0211124A (pt) |
CA (1) | CA2453554A1 (pt) |
GT (1) | GT200200148A (pt) |
IL (1) | IL159811A0 (pt) |
MX (1) | MXPA04000372A (pt) |
NZ (1) | NZ530992A (pt) |
PA (1) | PA8550401A1 (pt) |
PE (1) | PE20030292A1 (pt) |
UY (1) | UY27380A1 (pt) |
WO (1) | WO2003006471A1 (pt) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7482366B2 (en) * | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
ATE493987T1 (de) | 2002-05-22 | 2011-01-15 | Amgen Inc | Aminopyrimidin-derivate zur verwendung als vanilloid-rezeptor-liganden zur behandlung von schmerzen |
CA2493667C (en) | 2002-08-08 | 2010-04-27 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
UA80295C2 (en) | 2002-09-06 | 2007-09-10 | Biogen Inc | Pyrazolopyridines and using the same |
DE10247271A1 (de) * | 2002-10-10 | 2004-08-26 | Grünenthal GmbH | Substituierte C-Imidazo[1,2-a]pyridin-3-yle |
DE602004004143T2 (de) * | 2003-07-25 | 2007-10-11 | Neurogen Corp., Branford | Imidazopyrimidine und triazolopyrimidine: benzodiazepinrezeptorliganden |
EP1880998A1 (en) * | 2003-07-25 | 2008-01-23 | Neurogen Corporation | Imidazo-pyrimidines and triazolo-pyrimidines: benzodiazepine receptor ligands |
ZA200600037B (en) * | 2003-07-25 | 2007-04-25 | Neurogen Corp | Imidazo-pyrimidines and triazolo-pyrimidines: Benzodiazepine receptor ligands |
CA2556239A1 (en) | 2004-02-11 | 2005-08-25 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
MY139645A (en) | 2004-02-11 | 2009-10-30 | Amgen Inc | Vanilloid receptor ligands and their use in treatments |
WO2005080355A1 (en) * | 2004-02-12 | 2005-09-01 | Neurogen Corporation | Imidazo-pyridazines, triazolo-pyridazines and related benzodiazepine receptor ligands |
US20080004269A1 (en) * | 2004-11-04 | 2008-01-03 | Yuelian Xu | Pyrazolylmethy Heteroaryl Derivatives |
WO2006089311A1 (en) | 2005-02-15 | 2006-08-24 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
US20070155738A1 (en) | 2005-05-20 | 2007-07-05 | Alantos Pharmaceuticals, Inc. | Heterobicyclic metalloprotease inhibitors |
US7709468B2 (en) * | 2005-09-02 | 2010-05-04 | Abbott Laboratories | Imidazo based heterocycles |
US7750000B2 (en) * | 2005-09-02 | 2010-07-06 | Bayer Schering Pharma Ag | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments |
PL2495016T3 (pl) | 2005-12-23 | 2020-06-01 | Ariad Pharmaceuticals, Inc. | Bicykliczne związki heteroarylowe |
WO2007133562A2 (en) * | 2006-05-08 | 2007-11-22 | Ariad Pharmaceuticals, Inc. | Monocyclic heteroaryl compounds |
MX2008014289A (es) | 2006-05-08 | 2008-11-26 | Ariad Pharma Inc | Compuestos heteroarilicos acetilenicos. |
CN101652069A (zh) * | 2007-03-27 | 2010-02-17 | 艾博特公司 | 新的基于咪唑并的杂环化合物 |
EP1974729A1 (en) | 2007-03-28 | 2008-10-01 | Santhera Pharmaceuticals (Schweiz) AG | Substituted imidazopyridine derivates as melanocortin- 4 receptor antagonists |
EP2072516A1 (en) * | 2007-12-21 | 2009-06-24 | Santhera Pharmaceuticals (Schweiz) AG | Substituted imidazopyridine derivates as Melancortin-4 receptor antagonists |
WO2009102761A1 (en) | 2008-02-12 | 2009-08-20 | Bristol-Myers Squibb Company | 1,2,3-triazoles as 11-beta hydroxysteroid dehydrogenase type i inhibitors |
WO2010056311A1 (en) | 2008-11-12 | 2010-05-20 | Ariad Pharmaceuticals, Inc. | Pyrazinopyrazines and derivatives as kinase inhibitors |
US10206921B2 (en) | 2009-06-03 | 2019-02-19 | The Regents Of The University Of California | Methods and compositions for treating a subject for central nervous system (CNS) injury |
EP2298296A1 (en) * | 2009-08-25 | 2011-03-23 | CNRS Centre National De La Recherche Scientifique | Composition and method for treating cognitive impairments in down syndrome subjects |
WO2011051342A1 (en) | 2009-10-30 | 2011-05-05 | Janssen Pharmaceutica Nv | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS |
AR080754A1 (es) | 2010-03-09 | 2012-05-09 | Janssen Pharmaceutica Nv | Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10 |
EP2575455A4 (en) * | 2010-06-03 | 2014-01-15 | Univ California | METHODS AND COMPOSITIONS FOR TREATING A SUBJECT FOR INJURY OF THE CENTRAL NERVOUS SYSTEM (CNS) |
KR101034040B1 (ko) * | 2010-08-16 | 2011-05-16 | 정동영 | 백업트랙터 |
EP2723744B1 (en) | 2011-06-27 | 2016-03-23 | Janssen Pharmaceutica, N.V. | 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES |
US20150374705A1 (en) | 2012-02-14 | 2015-12-31 | Shanghai Institues for Biological Sciences | Substances for treatment or relief of pain |
US9669035B2 (en) | 2012-06-26 | 2017-06-06 | Janssen Pharmaceutica Nv | Combinations comprising PDE 2 inhibitors such as 1-aryl-4-methyl-[1,2,4]triazolo-[4,3-A]]quinoxaline compounds and PDE 10 inhibitors for use in the treatment of neurological of metabolic disorders |
WO2014009305A1 (en) | 2012-07-09 | 2014-01-16 | Janssen Pharmaceutica Nv | Inhibitors of phosphodiesterase 10 enzyme |
CA2815506C (en) | 2012-12-12 | 2018-12-11 | Ariad Pharmaceuticals, Inc. | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride |
ME03580B (me) | 2014-02-13 | 2020-07-20 | Incyte Corp | Ciklopropilamini kao lsd1 inhibitori |
EP3105219B9 (en) | 2014-02-13 | 2018-10-03 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
ES2901711T3 (es) | 2014-02-13 | 2022-03-23 | Incyte Corp | Ciclopropilaminas como inhibidores de LSD1 |
WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
WO2016007731A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyridines and imidazopyrazines as lsd1 inhibitors |
US9695180B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors |
WO2016007727A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
PL3240785T3 (pl) | 2014-12-29 | 2021-12-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inhibitory drobnocząsteczkowe dehydrogenazy mleczanowej i sposoby ich wykorzystania |
SG11201708047UA (en) | 2015-04-03 | 2017-10-30 | Incyte Corp | Heterocyclic compounds as lsd1 inhibitors |
MY189367A (en) | 2015-08-12 | 2022-02-08 | Incyte Corp | Salts of an lsd1 inhibitor |
AR109452A1 (es) | 2016-04-22 | 2018-12-12 | Incyte Corp | Formulación farmacéutica de un inhibidor de lsd1 y método de tratamiento |
WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
EP3886854A4 (en) | 2018-11-30 | 2022-07-06 | Nuvation Bio Inc. | PYRROLE AND PYRAZOLE COMPOUNDS AND METHODS OF USE THERE |
CN111662270A (zh) * | 2019-03-05 | 2020-09-15 | 中国医学科学院药物研究所 | 碘同位素标记苄苯醚衍生物、及其制法和药物组合物与用途 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989001333A1 (en) * | 1987-08-07 | 1989-02-23 | The Australian National University | IMIDAZO[1,2-b]PYRIDAZINES |
JPH11505524A (ja) * | 1995-05-01 | 1999-05-21 | 藤沢薬品工業株式会社 | イミダゾ1,2−aピリジンおよびイミダゾ1,2−aピリデジン誘導体、および骨吸収阻害剤としてのその用途 |
GB9801538D0 (en) | 1998-01-23 | 1998-03-25 | Merck Sharp & Dohme | Pharmaceutical product |
GB9805559D0 (en) | 1998-03-16 | 1998-05-13 | Merck Sharp & Dohme | A combination of therapeutic agents |
GB9805557D0 (en) | 1998-03-16 | 1998-05-13 | Merck Sharp & Dohme | A combination of therapeutic agents |
GB9805561D0 (en) | 1998-03-16 | 1998-05-13 | Merck Sharp & Dohme | A combination of therapeutic agents |
US6358949B1 (en) | 1999-04-02 | 2002-03-19 | Neurogen Corporation | Aryl and hetroaryl fused aminoalkyl-imidazole derivatives: selective modulators of bradykinin B2 receptors |
US6271241B1 (en) | 1999-04-02 | 2001-08-07 | Neurogen Corporation | Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors |
US6380210B1 (en) | 1999-04-02 | 2002-04-30 | Neurogen Corporation | Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors |
US6420365B1 (en) | 2000-01-18 | 2002-07-16 | Neurogen Corporation | Imidazopyridines and related derivatives as selective modulators of bradykinin B2 receptors |
WO2002002557A2 (en) * | 2000-06-30 | 2002-01-10 | Neurogen Corporation | 2-phenylimidazo[1,2-a]pyridine derivatives: a new class of gaba brain receptor ligands |
PA8535601A1 (es) | 2000-12-21 | 2002-11-28 | Pfizer | Derivados benzimidazol y piridilimidazol como ligandos para gabaa |
-
2001
- 2001-07-12 IL IL15981101A patent/IL159811A0/xx unknown
-
2002
- 2002-07-11 GT GT200200148A patent/GT200200148A/es unknown
- 2002-07-12 BR BR0211124-1A patent/BR0211124A/pt not_active IP Right Cessation
- 2002-07-12 JP JP2003512241A patent/JP2005505518A/ja active Pending
- 2002-07-12 CN CNA2008100019411A patent/CN101220027A/zh active Pending
- 2002-07-12 CA CA002453554A patent/CA2453554A1/en not_active Abandoned
- 2002-07-12 PE PE2002000626A patent/PE20030292A1/es not_active Application Discontinuation
- 2002-07-12 WO PCT/US2002/022130 patent/WO2003006471A1/en active IP Right Grant
- 2002-07-12 UY UY27380A patent/UY27380A1/es not_active Application Discontinuation
- 2002-07-12 KR KR10-2004-7000563A patent/KR20040015356A/ko not_active Application Discontinuation
- 2002-07-12 US US10/194,852 patent/US6936617B2/en not_active Expired - Fee Related
- 2002-07-12 EP EP02749983A patent/EP1406906A1/en not_active Withdrawn
- 2002-07-12 MX MXPA04000372A patent/MXPA04000372A/es active IP Right Grant
- 2002-07-12 AR ARP020102628A patent/AR036168A1/es unknown
- 2002-07-12 NZ NZ530992A patent/NZ530992A/en unknown
- 2002-07-12 CN CNB028166965A patent/CN100369912C/zh not_active Expired - Fee Related
- 2002-07-12 PA PA20028550401A patent/PA8550401A1/es unknown
-
2005
- 2005-08-29 US US11/214,345 patent/US20060014746A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US6936617B2 (en) | 2005-08-30 |
KR20040015356A (ko) | 2004-02-18 |
UY27380A1 (es) | 2003-02-28 |
EP1406906A1 (en) | 2004-04-14 |
US20030207885A1 (en) | 2003-11-06 |
PE20030292A1 (es) | 2003-04-03 |
US20060014746A1 (en) | 2006-01-19 |
IL159811A0 (en) | 2004-06-20 |
WO2003006471A1 (en) | 2003-01-23 |
CA2453554A1 (en) | 2003-01-23 |
JP2005505518A (ja) | 2005-02-24 |
CN1553916A (zh) | 2004-12-08 |
CN101220027A (zh) | 2008-07-16 |
PA8550401A1 (es) | 2004-02-07 |
NZ530992A (en) | 2005-06-24 |
CN100369912C (zh) | 2008-02-20 |
MXPA04000372A (es) | 2004-07-23 |
AR036168A1 (es) | 2004-08-18 |
GT200200148A (es) | 2003-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0211124A (pt) | Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos para alterar a atividade de transdução de sinal de receptores gabaa, para o tratamento de ansiedade, depressão, distúrbio do sono, esquizofrenia, distúrbio de hiperatividade-falta de atenção, ou para a melhora de memória, e para demonstrar a presença de receptores gabaa em uma célula ou amostra de tecido, composição farmacêutica embalada, e, uso de um composto ou sal | |
BR0116385A (pt) | Composto, composição farmacêutica, embalagem, métodos para alterar a atividade transdutora de sinal de um receptor de gabaa, para tratar ansiedade, depressão, um distúrbio do sono, esquizofrenia, distúrbio do déficit de atenção hiperatividade ou para a memória, para demonstrar a presença de um receptor de gabaa em uma amostra de célula ou tecido e em uma seção de tecido uso de um composto, e, processo para preparar um composto | |
BRPI0513475A (pt) | derivados quinazolin-4-il-piperidina e cinolin-4-il-piperidina como inibidores de pde10 no tratamento de distúrbios do snc | |
DE60001983D1 (de) | Bicyclische und tricyclische heteroaromatische verbindungen | |
BR0113300A (pt) | Composto ou um sal deste farmaceuticamente aceitável, composição farmacêutica, método para o tratamento de uma doença ou distúrbio associados com o agonismo patogênico, agonismo inverso ou antagonismo do receptor de gabaa, uso de um composto ou um sal, é, métodos para localização dos receptores de gabaa em uma amostra de tecido, de inibição da ligação de um composto de benzodiazepina a um receptor de gabaa, e para a alteração da atividade de transdutora de sinal dos receptores de gabaa | |
BR0208179A (pt) | Composto, composição farmacêutica, métodos para tratar distúrbios associados com o receptor 5-ht6, distúrbios cognitivos, distúrbios da mémoria, psicose, esquizofrenia, e ansiedade, e, uso de um composto | |
ATE293448T1 (de) | Benzo(d)azepin-derivative als 5-ht6-rezeptor- antagonisten | |
PA8637601A1 (es) | Compuestos moduladores de la actividad de c-kit y usos de los mismos | |
CL2003001814A1 (es) | Compuestos derivados de 1,3,8-triazaespiro[4,5]decan-4-ona jidroxialquil sustituidos, moduladores del receptor orl-1; compuestos intermediarios; composicion farmaceutica que contiene dichos compuestos; procedimiento de preparacion de la composicion f | |
EA199700156A1 (ru) | Производные индола как антагонисты рецептора 5-нт | |
BRPI0415769A (pt) | alcanaminas de diidrobenzofuranila e composições farmacêuticas contendo-as | |
BRPI0409986A (pt) | derivados de pirimidina fundida com atividade de crf | |
BR0109235A (pt) | Derivados do ácido carboxìlico como antagonistas ip | |
WO2002002557A3 (en) | 2-phenylimidazo[1,2-a]pyridine derivatives: a new class of gaba brain receptor ligands | |
DK1377586T3 (da) | Tricykliske diazepiner som tocolytiske oxytocinreceptorantagonister | |
BR0315056A (pt) | Compostos tendo tanto atividade agonista nicotìnica de alfa7 quanto atividade antagonista de 5ht3 para o tratamento de doenças do sistema nervoso central | |
BRPI0517955A (pt) | indolizinas substituìdas e derivados como agentes de snc | |
BRPI0417520A (pt) | 1h-pirrolo[3,2-b, 3,2-c, e 2,3-c]piridina-2-carboxamidas substituìdas e análogos relatados como inibidores de caseìna cinase i-epsilon | |
EA200501595A1 (ru) | Азабициклические производные в качестве антагонистов мускаринового рецептора | |
BR0015540A (pt) | Antagonistas do receptor de adenosina e métodos de preparação e uso dos mesmos | |
BR0211561A (pt) | Compostos e composições de 5-arilsulfonil indóis tendo afinidade para receptor 5-ht6 e seus usos | |
BRPI0514463A (pt) | antagonistas do receptor de 5-ht7 | |
BRPI0520579A2 (pt) | composto, processo para a preparação de um composto, método para o tratamento de uma desordem do sistema nervoso central relacionada a ou afetada pelo receptor 5-ht6, composição farmacêutica, uso do composto e método para testar antagonistas e antagonistas com seletividade para o receptor 5-ht6 | |
GT200500319A (es) | Algunos metabolitos derivados de [1,4]diazepino[6,7,1-ij]quinolina y metodos para la preparacion y usos de los mismos. | |
BRPI0409302A (pt) | derivados azabiciclo como antagonistas de recetores muscarìnicos, método para sua preparação e composição farmacêutica contendo os mesmos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A E 8A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2060 DE 29/06/2010. |